Published in Neurosci Lett on May 22, 1989
The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol (2010) 1.05
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J Neural Transm (Vienna) (2012) 0.80
Association between serotonin denervation and resting-state functional connectivity in mild cognitive impairment. Hum Brain Mapp (2017) 0.75
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. Neurosci Lett (1986) 2.01
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) (1984) 1.78
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res (1997) 1.56
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Clozapine-induced hypersalivation and the alpha 2 adrenoceptor. Br J Psychiatry (1995) 1.51
Recommended minimum data to be collected in research studies on Alzheimer's disease. The MRC (UK) Alzheimer's Disease Workshop Steering Committee. J Neurol Neurosurg Psychiatry (1989) 1.41
Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol (1978) 1.35
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) (1978) 1.29
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
Neuronal calcium-binding proteins and schizophrenia. Schizophr Res (2002) 1.19
Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm (Vienna) (2007) 1.14
Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol (2007) 1.13
Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett (1983) 1.12
Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem (1989) 1.11
Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord (1987) 1.06
Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature (1983) 1.04
Does phenylethylamine cause schizophrenia? Lancet (1976) 1.02
Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia? Commun Psychopharmacol (1978) 1.02
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci Lett (1998) 1.00
Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport (1996) 0.98
The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res (2006) 0.98
Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients. J Neurochem (1995) 0.97
The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol (2003) 0.96
Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS. Neuroreport (1999) 0.95
Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia. Neurosci Lett (1995) 0.95
Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr Res (2004) 0.94
Serotonin concentrations and turnover in brains of depressed suicides. Brain Res (1989) 0.94
Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex. J Psychiatr Res (2001) 0.92
Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry (1987) 0.92
Pre-frontal structural and functional deficits associated with individual differences in schizotypal personality. Schizophr Res (1992) 0.92
Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol (1992) 0.92
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci (1992) 0.91
Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain. J Psychopharmacol (2008) 0.91
Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci (1985) 0.91
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett (1992) 0.91
Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA (1985) 0.91
[3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm (1989) 0.90
Recombinant DNA studies on stored necropsy brain samples from patients with Huntington's chorea. J Clin Pathol (1985) 0.90
Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol (1986) 0.90
Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals (1993) 0.90
Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type. Neurosci Lett (1984) 0.89
Effects of tranylcypromine stereoisomers on monamine oxidation in man. Br J Clin Pharmacol (1980) 0.89
Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet (1988) 0.89
Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J Neural Transm Suppl (2007) 0.88
Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. Eur J Neurosci (2010) 0.88
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm (1978) 0.88
[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol (1985) 0.88
3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm (1989) 0.87
Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls, and normal controls. A magnetic resonance imaging and neuropsychological evaluation. Arch Gen Psychiatry (1990) 0.87
Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol (1999) 0.87
Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behav Brain Res (1996) 0.86
Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. J Neural Transm Suppl (2006) 0.86
Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci Lett (1987) 0.85
Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch Gen Psychiatry (1987) 0.85
Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci Lett (1986) 0.85
Neuropeptides in Alzheimer's disease: a postmortem study. Regul Pept (1989) 0.84
Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J Psychopharmacol (2006) 0.84
Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology (1988) 0.84
Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett (2001) 0.84
Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience (1988) 0.84
An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res (1992) 0.84
Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset. Neurosci Lett (1985) 0.84
Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett (2001) 0.84
Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol (1993) 0.84
Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats. Neuroscience (2003) 0.83
Deficient production of tyramine and octopamine in cases of depression. Nature (1979) 0.83
Trace amine deficit in depressive illness: the phenylalanine connexion. Acta Psychiatr Scand Suppl (1980) 0.82
Effects of excitotoxic lesions of the rat prefrontal cortex on CREB regulation and presynaptic markers of dopamine and amino acid function in the nucleus accumbens. Eur J Neurosci (1999) 0.82
Neuroanatomical correlates of skin conductance orienting in normal humans: a magnetic resonance imaging study. Psychophysiology (1991) 0.82
Increased brain 3-hydroxykynurenine in Huntington's disease. Lancet (1989) 0.82
The effect of urinary pH and flow rate on monoamine output. Clin Chim Acta (1978) 0.82
Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol (1989) 0.81
Lithium prophylaxis inhibits choline transport in post-mortem brain. Lancet (1986) 0.81
Region specific changes in forebrain 5-hydroxytryptamine1A and 5-hydroxytryptamine2A receptors in isolation-reared rats: an in vitro autoradiography study. Neuroscience (2004) 0.81
Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy. J Chromatogr (1991) 0.81
Decreased brown adipose tissue thermogenic activity following a reduction in brain serotonin by intraventricular p-chlorophenylalanine. Biosci Rep (1987) 0.80
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol (2008) 0.80
Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain. J Psychopharmacol (1998) 0.79
Arachidonic acid: a common link in the biology of schizophrenia? Arch Gen Psychiatry (1994) 0.79
Alzheimer-like brain monoamine deficits in adults with Down's syndrome. Lancet (1985) 0.79
Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry (2002) 0.79
Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response. Mod Probl Pharmacopsychiatry (1983) 0.79
Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique. J Chromatogr (1981) 0.79
An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease. J Neural Transm Gen Sect (1995) 0.78
Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine. Br J Pharmacol (1987) 0.78
Glutamate stimulates dopamine release from cortical and limbic rat brain in vitro. Eur J Pharmacol (1993) 0.78
Striatal dopamine and homovanillic acid in Huntington's disease. J Neural Transm (1986) 0.78
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease. Br J Clin Pharmacol (1980) 0.78
Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation. Brain Res (1987) 0.78
Thioridazine is not specific for limbic dopamine receptors. Lancet (1982) 0.78
Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl (1983) 0.77
Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res (1983) 0.77
Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. Eur Arch Psychiatry Neurol Sci (1988) 0.77
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. Adv Neurol (1983) 0.77
Deficits of [3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci Lett (1997) 0.77
Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett (1998) 0.77
Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease. J Neurochem (1984) 0.77